From Urgency To Execution: TFS Delivers Rapid Results In A High-Stakes Dry Eye Disease Trial

TFS HealthScience was engaged to manage a time-sensitive Phase III trial in dry eye disease. With rigid timelines and ambitious development goals, the study required rapid activation of 25 U.S. sites, enrollment of 250 patients within six weeks, and final top-line results within three weeks of study completion. Primary endpoints included changes in SANDE scores and Lissamine Green conjunctival staining at Days 14 and 28. TFS met these aggressive goals through precision project management, leveraging strong site relationships, ophthalmology-specific expertise, and data-driven site selection. Historical performance metrics and trusted partnerships enabled accelerated feasibility, reduced risk, and improved responsiveness. A cohesive full-service team ensured close coordination across clinical operations, monitoring, data management, and biostatistics.
Despite the trial's complexity and time constraints, TFS delivered high-quality results on schedule. The sponsor benefited from minimized feasibility costs and a streamlined execution process, allowing them to advance their ophthalmology pipeline confidently. This case underscores TFS’s capacity to execute critical trials efficiently in specialized therapeutic areas through expert leadership and strategic operational planning.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.